Pro Share Advisors LLC Allovir, Inc. Transaction History

Pro Share Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$2.15 - $3.64 $5,484 - $9,285	2,551 Added 22.17%	14,057 $30,000
Q2 2023 Aug 10, 2023	BUY	$3.17 - $5.82 $4,342 - $7,973	1,370 Added 13.52%	11,506 $39,000
Q1 2023 May 11, 2023	SELL	$3.94 - $7.05 $6,166 - $11,033	-1,565 Reduced 13.37%	10,136 $39,000
Q4 2022 Feb 02, 2023	BUY	$4.7 - $9.98 $2,110 - $4,481	449 Added 3.99%	11,701 $60,000
Q3 2022 Nov 04, 2022	BUY	$4.13 - $8.79 $46,470 - $98,905	11,252 New	11,252 $90,000
Q2 2022 Aug 01, 2022	SELL	$3.26 - $7.06 $40,075 - $86,788	-12,293 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$6.75 - $13.52 $22,443 - $44,954	-3,325 Reduced 21.29%	12,293 $84,000
Q4 2021 Feb 08, 2022	SELL	$12.94 - $25.99 $26,798 - $53,825	-2,071 Reduced 11.71%	15,618 $201,000
Q3 2021 Nov 12, 2021	SELL	$16.97 - $25.06 $28,187 - $41,624	-1,661 Reduced 8.58%	17,689 $443,000
Q2 2021 Aug 13, 2021	BUY	$19.44 - $25.06 $47,122 - $60,745	2,424 Added 14.32%	19,350 $382,000
Q1 2021 May 14, 2021	BUY	$20.81 - $45.5 $60,473 - $132,223	2,906 Added 20.73%	16,926 $396,000
Q4 2020 Feb 09, 2021	BUY	$23.94 - $46.81 $335,638 - $656,276	14,020 New	14,020 $539,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $50.3M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.